Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
Pomerantz LLP has launched an investigation into EyePoint, Inc. (NASDAQ: EYPT) regarding potential securities fraud or unlawful business practices. The probe follows two significant clinical setbacks for the company's drug candidate, DURAVYU™. In August 2026, the LUGANO Phase 3 trial failed to meet visual acuity benchmarks compared to Regeneron Pharmaceuticals' Eylea, causing a nearly 67% drop in share price. A second blow occurred in October 2026 when the LUCIA Phase 3 trial also failed to demonstrate non-inferiority against the standard of care. In response to these failures, EyePoint terminated its late-stage wet AMD clinical program and announced a massive 53% workforce reduction to pivot toward diabetic macular edema programs. The stock plummeted over 85% following the second announcement.
Topics: class action lawsuit clinical trial failure layoffs securities fraud investigation stock price volatility
Read the full article at PR Newswire
Part of the story Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures (3 articles)